Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

NCT04449861 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Carcinoma Extensive Disease

Interventions

DRUG: Durvalumab plus chemotherapy

Sponsor

AstraZeneca